Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/01443615.2016.1229277 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis.
Cancer Med
January 2025
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Background: Borderline ovarian tumors (BOTs) differ from ovarian carcinomas in their clinical presentation and behavior, yet their molecular characteristics remain poorly understood. This study aims to address this gap by integrating whole-exome sequencing (WES) and RNA sequencing (RNA-seq) to compare BOTs with high-grade serous carcinoma (HGSC), endometrioid carcinoma (EC), and clear-cell carcinoma (CCC).
Objective: To elucidate the molecular features of BOTs and evaluate their similarities and differences in comparison to HGSC, EC, and CCC.
Endometrioid adenocarcinoma of the colon arising from rare malignant transformation of extra-gonadal endometrioma.
Gynecol Oncol Rep
February 2025
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY, USA.
Background: Endometriosis is a common condition with a rare malignant potential. We report a case of a patient with a colon mass who underwent surgery for malignant endometriosis associated cancer.Case: A 70-year-old woman with a pelvic mass who was lost to follow-up for 6 years represented with an enlarging pelvic mass involving the sigmoid colon.
View Article and Find Full Text PDFEndometrial cancer with para-aortic lymph node metastasis following medroxyprogesterone acetate therapy: A case report.
J Obstet Gynaecol Res
January 2025
Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical University, Tochigi, Japan.
Medroxyprogesterone acetate (MPA) is a promising fertility-sparing treatment for early stage endometrial cancer; however, it has a high recurrence rate and is inferior to surgery. Although the site of recurrence is mostly the endometrium, we here report a case of metastatic recurrence to the para-aortic lymph node with endometrial recurrence despite a careful follow-up. A 31-year-old woman was diagnosed with grade 1 endometrioid carcinoma, stage IA without myometrial invasion.
View Article and Find Full Text PDFProfiling Sociodemographic Risk Factors and Clinical Outcomes of Women with Endometrial Cancer in Puerto Rico: The Central Role of Obesity and Obstetric Features.
J Racial Ethn Health Disparities
January 2025
Puerto Rico Biobank, Ponce Health Sciences University-Moffitt Cancer Center U54 Partnerships to Advance Cancer Health Equity (PACHE), Ponce, USA.
Introduction: Incidence of endometrial cancer (EC) in Hispanic/Latina (H/L) women are higher compared to other race/ethnicities in the United States. EC is the third most common cancer and the fourth cause of cancer-related deaths in Puerto Rican women, yet demographic and clinical information is limited. High rates of EC risk factors such as obesity, diabetes mellitus type 2 (DM2) and hypertension (HTN) have been documented in the Puerto Rican population.
View Article and Find Full Text PDFClinicopathological characteristics and survival outcomes of women aged ≤45 and >45 years with endometrial adenocarcinoma in tertiary referral hospital: a 21-year cohort study.
BMJ Open
January 2025
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Objective: This study aimed to compare clinicopathological characteristics and oncological outcomes in patients with endometrial cancer aged ≤45 and >45 years, with a focus on identifying distinct traits and prognostic factors in younger patients.
Design: A retrospective cohort study.
Setting: The study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, with a restricted study population from 1996 to 2016.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!